Just 10 days after announcing plans to let go of its iNK programs as part of a major portfolio and workforce restructuring, Editas Medicine has found a buyer for the cell technologies in the form of Shoreline Biosciences.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,